bi-1607
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 28, 2022 (NCT05555251)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FCGR2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06784648 | Phase 1/Phase 2 (Phase 2) | Dec 11, 2024 | BioInvent International AB, Merck |
| NCT05555251 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2022 | BioInvent International AB |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioInvent International AB | For profit | 2 | 2 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1